He cited Malawi, South Sudan, Liberia, Mauritania, Gambia, Sierra Leone,[9] Guinea, Comoros and the Democratic Republic of Congo as examples.

[10] Also in July 2021, the European Investment Bank committed to fund Senegal's first COVID-19 vaccine production factory, at Institut Pasteur de Dakar.

By the end of 2022, this factory is expected to manufacture up to 25 million doses of a licensed COVID-19 vaccine per month.

This is part of a wide effort by the European Investment Bank to address the health and economic impact of COVID-19.

[11][12][13] Meanwhile, BioNTech and the European Union are collaborating to assess mRNA vaccine production facilities in Rwanda and Senegal.

[14][15][16][17] In seven African countries (Botswana, Cape Verde, Mauritius, Morocco, Rwanda, Seychelles, Tunisia) the entire targeted population had been fully vaccinated by the end of 2021.

[19][20][21] Starting in 2022, the Biovac Institute in Cape Town will manufacture 100 million doses annually of the Pfizer-BioNTech COVID-19 vaccine exclusively for African countries.

[22] Algeria's pharmaceutical minister Lotfi Benbahmad announced that an agreement had been reached to produce Sputnik V COVID-19 vaccine at Saidal's manufacturing plant in Constantine.

[48] On 21 July 2021, Cameroon received 303,050 doses of the Janssen COVID-19 vaccine donated by the United States.

By the end of October 2021, 269,914 doses had been administered and 112,541 persons (5% of the targeted population) were fully vaccinated.

By the end of November 2021, 644,918 doses had been administered and 474,446 persons (21% of the targeted population) were fully vaccinated.

By the end of December 2021, 758,891 doses had been administered and 583,609 persons (25% of the targeted population) were fully vaccinated.

[68] On 30 December 2021 and 3 January 2022, it received more than 1.6 million doses of the Pfizer-BioNTech vaccine, donated by the United States.

[41][87][88] On 31 July 2021, Kenya took delivery of 410,000 doses of the Oxford-AstraZeneca vaccine donated by the United Kingdom.

[89] On 23 August 2021, Kenya received a donation of 880,460 doses of the Moderna COVID‑19 vaccine from the United States.

[92] On 25 July 2021, Liberia took delivery of 302,400 doses of the Janssen COVID-19 vaccine donated by the United States.

[96] In July and October 2021, the United States donated 638,750 doses of the Janssen vaccine to Madagascar.

[44][100][101] On 28 June 2021, Mali gave 97,200 doses of the Oxford-AstraZeneca vaccine to Côte d'Ivoire because of their short expiry date.

[108][109] In July and September 2021, Mozambique received 638,400 doses of the Janssen COVID-19 vaccine donated by the United States.

[61][118] In late July 2021, it received 302,400 doses of the Janssen COVID-19 vaccine donated by the United States.

[121] The rollout began after the delivery of 4 million Oxford-AstraZeneca, with more doses donated by India and MTN.

[142] On 27 August 2022, Somalia received more than 1.6 million doses of the Janssen vaccine from the Czech Republic and Sweden through COVAX.

Health officials decided on 15 April to stop using the doses donated by the AU and MTN due to their short expiry date.

[155] On 14 July 2021, Health Minister Dorothy Gwajima announced that Tanzania was going to receive 300,000 doses through COVAX.

[157] On 25 July 2021, Tanzania received 1,058,400 doses of the Janssen COVID-19 vaccine through COVAX, donated by the United States.

In January 2021, Johnson & Johnson, which held trials for its Janssen COVID-19 vaccine in South Africa, reported the level of protection against moderate to severe COVID-19 infection was 72% in the United States, but 57% in South Africa.

[172] On 6 February 2021, The Financial Times reported that provisional trial data from a study undertaken by South Africa's University of the Witwatersrand in conjunction with Oxford University demonstrated reduced efficacy of the Oxford–AstraZeneca COVID-19 vaccine against the 501.V2 variant.

The study found that in a sample size of 2,000 the AZD1222 vaccine afforded only "minimal protection" in all but the most severe cases of COVID-19.

[173] On 7 February 2021, the Minister for Health for South Africa suspended the planned deployment of around 1 million doses of the vaccine whilst they examine the data and await advice on how to proceed.

[174] In February, Moderna reported that the current vaccine produced only one-sixth of the antibodies in response to the South African variant compared with the original virus.